Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 0.47 |
| ▸ | PDE4A | P27815 | 5/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5044212 | 0.88 | PDE4B (0.40) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL4638391 | 0.77 | PDE4B (0.52) | PDE4BPDE4APDE4CPDE4DNPC1 | |
| SCHEMBL4923833 | 0.76 | HTT (0.49) | RAB9A | |
| SCHEMBL9325871 | 0.75 | PDE4A (0.59) | PDE4BPDE4APDE4CPDE4DNPC1 | |
| SCHEMBL6114258 | 0.75 | HPGD (0.51) | — | |
| SCHEMBL14053273 | 0.74 | CYP1A2 (0.42) | RAB9A | |
| SCHEMBL3039158 | 0.74 | SLC9A1 (0.41) | NPC1RAB9A | |
| Bicarbonate SCHEMBL9574485 | 0.73 | PDE4B (0.60) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3428206 | 0.73 | HDAC8 (0.44) | — | |
| SCHEMBL1415417 | 0.72 | ACMSD (0.51) | PDE4BPDE4APDE4CPDE4DMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1456202-B1 | BENZOTHIAZOLES | HOFFMANN LA ROCHE (CH) | 2005-11-09 | — | — | EP | disclosed |
| EP-1456202-A1 | BENZOTHIAZOLES | F. Hoffman-la Roche AG (CH) | 2004-09-15 | — | — | EP | disclosed |
| US-6734179-B2 | SULFUR COMPOUNDS SUCH AS 4-FLUORO-N-(4-METHOXY-7-(TETRAHYDRO-PYRAN-4-YL)-BENZOTHIAZOL-2-YL) -BENZAMIDE, USED AS PREFERENTIAL ADENOSINE RECEPTOR LIGANDS FOR THE PROPHYLAXIS OF NEURODEGENERATIVE DISORDERS | HOFFMANN-LA ROCHE INC. | 2004-05-11 | — | — | US | disclosed |
| US-20030144288-A1 | Benzothiazoles | F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) | 2003-07-31 | — | — | US | disclosed |
| WO-2003053961-A1 | BENZOTHIAZOLES | F. HOFFMAN-LA ROCHE AG (CH) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144288-A1 | Benzothiazoles | ADORA2A, ADORA1, ADORA2B | PDE4B 648/4885PDE4A 469/4885PDE4C 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.